The Belgian Association of Clinical Research Professionals has presented its European outstanding leadership award
The Belgian Association of Clinical Research Professionals has presented its European outstanding leadership award to Jan Geissler and Dr. Georges Niset.
The group presented Geissler, director of the European Patients' Academy on Therapeutic Innovation, EUPATI) and patient advocate, with the ACRP.be award “in recognition of his exceptional performance and leadership within EUPATI, in particular by addressing training issues and by improving the availability of both patient-centric information for the public as well as educated patient experts that have the capacity and capability to contribute to R&D.”
The leadership award is presented annually to individuals who have demonstrated exceptional performance, achievement and sustained service toward the goals of ACRP and the contributions to the advancement of clinical research in general.
"I feel deeply honored to accept this award on behalf of my fellow patient advocates as well as the EUPATI team," Geissler said. "The fact that this award of research professionals is being provided to patient advocates, as well as to EUPATI being a partnership of patient organizations, academia and industry, is a reflection of the paradigm shift: patients are increasingly seen as true partners in medicines R&D. The ACRP and EUPATI share an important mission: building the capacity and capability of both clinical research professionals as well as expert patients."
The other recipient, Dr. Georges Niset, is Secretary of the Ethics Committee at Erasme-ULB in Belgium.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.